AbbVie Provides Update on Phase 2 Results for Emraclidine in ...
NORTH CHICAGO, Ill., Nov. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, did not meet their primary endpoint of showing a ...
Phase 2 schizophrenia fails will cost AbbVie about $3.5B
Jan 10, 2025 · AbbVie acquired Cerevel in December 2023 for a hefty $8.7 billion.Emraclidine was the shining gem of Cerevel’s pipeline before its phase 2 flops. The drug is also being studied in Alzheimer’s ...
AbbVie Provides Update on Phase 2 Results for Emraclidine in …
NORTH CHICAGO, Ill., Nov. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment...
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints ...
Nov 11, 2024 · On Monday, AbbVie Inc (NYSE: ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.
AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset
Nov 11, 2024 · The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, which put the drug at the center of expectations.
AbbVie’s $9B bet collapses as closely watched schizophrenia drug …
Nov 11, 2024 · AbbVie lost about $40 billion in market value Monday morning after an experimental drug the company had bet heavily on failed two important clinical trials. The drug, called emraclidine, was developed by Pfizer spinout Cerevel Therapeutics, which AbbVie recently acquired for almost $9 billion.
Emraclidine for Schizophrenia Fails to Meet Primary Endpoints in …
Nov 11, 2024 · AbbVie announced that 2 of its phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia experiencing acute psychotic symptoms, did not meet their primary endpoint of a statistically significant improvement in the change from baseline in …
AbbVie: Emraclidine's Failure Eliminates An Important Growth …
Nov 11, 2024 · Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of...
AbbVie Provides Update on Phase 2 Results for Emraclidine in ...
NORTH CHICAGO, Ill., Nov. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment...
AbbVie Provides Update on Phase 2 Results for Emraclidine in …
Nov 11, 2024 · AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing...